US Diabetic Retinopathy Market Overview:
As per MRFR analysis, the US Diabetic Retinopathy Market Size was estimated at 1.81 (USD Billion) in 2023. The US Diabetic Retinopathy Market Industry is expected to grow from 2(USD Billion) in 2024 to 4 (USD Billion) by 2035. The US Diabetic Retinopathy Market CAGR (growth rate) is expected to be around 6.504% during the forecast period (2025 - 2035).
Key US Diabetic Retinopathy Market Trends Highlighted
The US Diabetic Retinopathy Market is seeing significant trends driven by the increasing prevalence of diabetes and a growing awareness of eye health among patients. One of the key market drivers is the rising number of diabetes cases, which has led to a proportional increase in diabetic retinopathy. As per the Centers for Disease Control and Prevention (CDC), millions of Americans are diagnosed with diabetes, resulting in more individuals at risk for diabetic eye diseases. This uptick in prevalence boosts demand for early screening and effective treatment options, leading to advancements in retinal imaging technology and laser therapy, making them pivotal in the market.Opportunities in the US Diabetic Retinopathy Market can be tapped into through innovations in telemedicine and digital health solutions. The COVID-19 pandemic highlighted the need for remote healthcare services, and companies are exploring telehealth platforms to facilitate patient screenings and consultations for diabetic retinopathy. This could expand access to care, especially for those in rural areas who may face barriers to visiting ophthalmologists or retina specialists. Recent trends also show an increase in the adoption of pharmacotherapy for managing diabetic retinopathy, including anti-VEGF injections and steroid implants. Furthermore, education efforts aimed at both healthcare providers and patients about the importance of regular eye examinations are gaining traction.The combination of technological advancements and increased awareness among patients is effectively shaping the landscape of the US Diabetic Retinopathy Market, creating an environment that encourages both treatment and prevention. As these developments continue to unfold, they are likely to redefine best practices in managing this prevalent condition.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
US Diabetic Retinopathy Market Drivers
Increasing Prevalence of Diabetes in the United States
The US Diabetic Retinopathy Market Industry is significantly driven by the increasing prevalence of diabetes, which is a leading cause of diabetic retinopathy. According to the Centers for Disease Control and Prevention (CDC), approximately 37 million Americans had diabetes in 2020, and this figure is anticipated to rise by about 54% by 2030. This increase in diabetes cases directly correlates to a higher incidence of diabetic retinopathy, as nearly one-third of adults with diabetes are estimated to have some stage of diabetic retinopathy.Organizations such as the American Diabetes Association are focused on awareness and prevention strategies, further emphasizing the need for timely screening and treatment, which is expected to boost the market for diabetic retinopathy interventions. The projections indicate a growing user base, which is vital for the US Diabetic Retinopathy Market Industry's growth.
Advancements in Medical Technology
Technological advancements in diagnostic and therapeutic devices for diabetic retinopathy are a significant driver for the US Diabetic Retinopathy Market Industry. Innovations such as Optical Coherence Tomography (OCT) and artificial intelligence-based diagnostic tools are revolutionizing the early detection and treatment of this condition. According to the Food and Drug Administration (FDA), over 100 new devices for the diagnosis and treatment of ocular conditions have been approved in recent years.Such advancements provide practitioners with better tools for intervention, which can lead to improved patient outcomes and greater market growth. The increase in FDA approvals signals a vibrant innovation landscape, promising a robust future for the US Diabetic Retinopathy Market Industry.
Rising Awareness and Screening Programs
There is a growing awareness about diabetic retinopathy and the importance of regular screenings in the US, significantly impacting the US Diabetic Retinopathy Market Industry. Various health organizations, including the National Eye Institute, have launched awareness campaigns to educate both patients and healthcare providers on the need for routine eye exams for diabetic patients. As a result, screening rates have recently increased, with reports indicating that about 73% of diabetic patients received eye examinations each year, a substantial rise from 64% a decade ago.This increase in awareness directly correlates with market demand for diagnostic solutions and treatment options for diabetic retinopathy, fostering a conducive environment for industry growth.
US Diabetic Retinopathy Market Segment Insights:
Diabetic Retinopathy Market Type Insights
The US Diabetic Retinopathy Market is categorized into various types, with the two primary types being Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR). Non-Proliferative Diabetic Retinopathy is characterized by the onset of retinal changes due to diabetes, initially presenting with mild symptoms but potentially leading to more severe sight-related issues if not treated. This type accounts for a majority holding in the overall diabetic retinopathy cases, making early detection and management crucial for preventing progression to the more advanced stage. It is often asymptomatic in the early stages, which presents a challenge for diagnosis; hence, regular screenings are vital for individuals with diabetes. Proliferative Diabetic Retinopathy, on the other hand, represents a more advanced stage where abnormal blood vessels grow on the retina, which increases the risk of vision loss significantly if intervention is not performed promptly. PDR tends to have a severe impact on an individual’s quality of life and requires more complicated treatment options, such as laser therapy and injections, which adds pressure on healthcare resources. The prevalence of both types is a direct reflection of the increasing cases of diabetes across the United States, with millions affected. Factors such as an aging population, rising obesity rates, and sedentary lifestyles contribute to this trend, thus creating a growing demand for therapeutic interventions to manage and treat these conditions. The awareness of diabetic retinopathy in the healthcare community is also evolving, with professionals emphasizing the importance of screening and education around diabetic complications. In summary, understanding the nuances of NPDR and PDR is essential for addressing the broader challenges posed by diabetic retinopathy within the US, particularly as the market aligns itself to provide better diagnostics and treatments tailored to these specific types. This segment holds significant potential for advancements, as continuous research and development, alongside efforts to raise public awareness, shape patient outcomes in meaningful ways.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Diabetic Retinopathy Market Treatment Insights
The Treatment segment of the US Diabetic Retinopathy Market plays a critical role in managing this chronic disease, which affects a significant portion of the population. This segmentation comprises various approaches, including Pharmacological Therapies, Laser Treatment, and Surgery. Pharmacological Therapies, which often utilize anti-VEGF injections, are pivotal for halting disease progression and preserving vision. They are widely adopted due to their effectiveness and have become a standard intervention for patients with diabetic retinopathy.Laser Treatment is well-established as an efficient method to manage retinal complications, leveraging precision to target affected areas and reduce the risk of severe vision loss. Its significance is underscored by its ability to provide immediate intervention that is vital in advanced stages of the disease. Lastly, Surgery is crucial for cases where other treatments are ineffective, demonstrating advancements in techniques like vitrectomy that have improved outcomes for patients facing severe visual impairment. The strong growth of this segment reflects the increasing prevalence of diabetes in the US, coupled with a rising awareness of diabetic retinopathy, presenting substantial opportunities for innovative treatments and improved patient care.
Diabetic Retinopathy Market End User Insights
The End User segment of the US Diabetic Retinopathy Market includes key players such as Hospitals and Clinics, Ophthalmology Centers, and Research Institutes, each playing a pivotal role in the diagnosis and treatment of diabetic retinopathy. Hospitals and Clinics represent a substantial component, offering comprehensive services and specialized care for patients suffering from diabetic-related vision issues. Ophthalmology Centers focus specifically on eye-related disorders, providing advanced diagnostic tools and therapeutic interventions that cater to a growing patient population.Research Institutes contribute significantly to this landscape by facilitating innovation and conducting clinical trials that drive the development of cutting-edge therapies and technologies for diabetic eye diseases. The increasing prevalence of diabetes in the US substantially influences demand across these segments, as effective management of diabetic retinopathy becomes crucial to preserving vision. Additionally, advancements in medical technology and increased awareness about early diagnosis further bolster the importance of these facilities in providing both treatment and patient education.
US Diabetic Retinopathy Market Key Players and Competitive Insights:
The US Diabetic Retinopathy Market has grown significantly in recent years, driven by the increasing prevalence of diabetes and the resulting demand for effective treatment options. This market encompasses a variety of therapeutic solutions, including pharmaceuticals and surgical interventions, aimed at addressing the vision complications associated with diabetic retinopathy. The competitive landscape is characterized by the presence of numerous players, each contributing to innovations in diagnostics, treatment modalities, and technologies that enhance patient outcomes. The landscape is influenced not only by established pharmaceutical giants but also by emerging biotechnology companies focusing on niche markets within the diabetic retinopathy space. As competition intensifies, companies are emphasizing product differentiation, establishing strategic partnerships, and investing in research to ensure a foothold in this lucrative market.Teva Pharmaceutical Industries has carved out a notable position within the US Diabetic Retinopathy Market through its extensive portfolio and commitment to accessibility. The company's strengths lie in its comprehensive range of generic and specialty medications, providing affordable treatment alternatives to patients. Teva is recognized for its focus on research and development, allowing it to adapt and expand its treatment options in response to evolving market needs. Furthermore, its established distribution channels ensure broad market reach, facilitating easier access to its products for healthcare providers and patients alike. Teva's operational efficiencies and focus on cost management help maintain competitive pricing, which is crucial in the context of a market where affordability is a significant factor in treatment selection.Genentech, a leader in the US Diabetic Retinopathy Market, is renowned for its innovative biotechnology solutions, particularly in developing novel therapies aimed at preventing vision loss in diabetic patients. The company's flagship products include anti-VEGF agents that have transformed the treatment landscape for diabetic retinopathy, providing effective options that enhance visual acuity and slow disease progression. Genentech's robust presence in the market is underpinned by a strong R&D pipeline, consistently delivering groundbreaking advancements that address unmet medical needs. The company has also engaged in strategic partnerships and collaborations with academic institutions and other firms to expand its product offerings and accelerate clinical development. Mergers and acquisitions have played a key role in strengthening Genentech's market position, enabling the integration of diversified therapeutic capabilities. The company’s commitment to patient support programs further reinforces its standing in the US, making it a trusted name among healthcare professionals and patients navigating the challenges posed by diabetic retinopathy.
Key Companies in the US Diabetic Retinopathy Market Include:
Teva Pharmaceutical Industries
Genentech
Aerie Pharmaceuticals
Novartis
Santen Pharmaceutical
Alimera Sciences
Lilly
Regeneron Pharmaceuticals
Horizon Therapeutics
Pfizer
Amgen
Roche
Allergan
PharmaEssentia
Bayer
US Diabetic Retinopathy Market Industry Developments
The US Diabetic Retinopathy Market has seen significant developments recently, particularly with the increasing focus on innovative treatment options to address the growing patient population suffering from this condition. Companies such as Regeneron Pharmaceuticals and Aerie Pharmaceuticals have been pivotal in advancing therapies, with Regeneron’s Eylea continuing to dominate the market due to its effectiveness in treating diabetic macular edema. In September 2023, Genentech announced an expansion of its geographic footprint for the Lucentis therapy, further enhancing patient access. Additionally, Novartis launched an initiative aimed at increasing awareness about diabetic retinopathy among healthcare providers and patients alike. In terms of mergers and acquisitions, Alimera Sciences announced in August 2023 its intention to acquire new therapeutic assets to strengthen its portfolio in this market. Growth metrics indicate an expanding market valuation for companies like Pfizer and Amgen, driven by increased investments in Research and Development and a focus on personalized medicine. Over the past few years, initiatives to enhance screening and early intervention, particularly during the COVID-19 pandemic when many patients deferred care, have highlighted underlying challenges and opportunities to improve outcomes in diabetic retinopathy management in the US.
US Diabetic Retinopathy Market Segmentation Insights
Diabetic Retinopathy Market Type Outlook
Non-Proliferative Diabetic Retinopathy (NPDR)
Proliferative Diabetic Retinopathy (PDR)
Diabetic Retinopathy Market Treatment Outlook
Pharmacological Therapies
Laser Treatment
Surgery
Diabetic Retinopathy Market End User Outlook
Hospitals & Clinics
Ophthalmology Centers
Research Institutes
Report Scope:
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 1.81(USD Billion) |
| MARKET SIZE 2024 | 2.0(USD Billion) |
| MARKET SIZE 2035 | 4.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.504% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Teva Pharmaceutical Industries, Genentech, Aerie Pharmaceuticals, Novartis, Santen Pharmaceutical, Alimera Sciences, Lilly, Regeneron Pharmaceuticals, Horizon Therapeutics, Pfizer, Amgen, Roche, Allergan, PharmaEssentia, Bayer |
| SEGMENTS COVERED | Type, Treatment, End User |
| KEY MARKET OPPORTUNITIES | Increasing prevalence of diabetes, Advancements in diagnostic technologies, Growth in telemedicine solutions, Development of targeted therapies, Rising awareness and education programs |
| KEY MARKET DYNAMICS | rising diabetic population, increasing awareness and screening, technological advancements in treatment, growing healthcare expenditure, favorable reimbursement policies |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Diabetic Retinopathy Market is expected to be valued at 2.0 billion USD in 2024.
The market is projected to grow to 4.0 billion USD by 2035.
The expected CAGR for the market during this period is 6.504%.
The market is primarily divided into Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy.
The market value for Non-Proliferative Diabetic Retinopathy is expected to be 1.2 billion USD in 2024.
The Proliferative Diabetic Retinopathy segment is expected to reach 1.6 billion USD by 2035.
Key players include Teva Pharmaceutical Industries, Genentech, Aerie Pharmaceuticals, and Novartis among others.
The market growth is driven by the rising prevalence of diabetes and increasing awareness about diabetic retinopathy.
Opportunities include advancements in treatment options and technology for early detection and management.
Current economic conditions can affect funding for healthcare and affect access to treatments for diabetic retinopathy.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
